<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="292">
  <stage>Registered</stage>
  <submitdate>25/08/2005</submitdate>
  <approvaldate>31/08/2005</approvaldate>
  <actrnumber>ACTRN12605000240640</actrnumber>
  <trial_identification>
    <studytitle>The effect of statin and fibrate therapy on vascular function in chronic kidney disease</studytitle>
    <scientifictitle>The effect of statin and fibrate therapy on vascular function in chronic kidney disease</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Cardiovascualr disease in patients with chronic kidney disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Atorvastatin 40mg, Gemfibrozil 600mg BD for 6 weeks.</interventions>
    <comparator>Placebo</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Post-ischaemic flow-mediated dilatation of the brachial artery.</outcome>
      <timepoint>Measured at baseline (week 0) and at the end of week 6.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Systemic arterial compliance (a measure of arterial elasticity).</outcome>
      <timepoint>Measured at baseline (week 0) and at the end of week 6.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Post-glyceryl trinitrate brachial artery vasodilatation.</outcome>
      <timepoint>Measured at baseline (week 0) and at end of week 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Lipid and lipoprotein concentration.</outcome>
      <timepoint>Measured at baseline (week 0) and at end of week 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. Apolipoprotein B, CIII and AI concentration.</outcome>
      <timepoint>Measured at baseline (week 0) and at end of week 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4. Markers of inflammation (CRP, IL-6), oxidative stress (plasma isoprostanes and dityrosine), nitric oxide bioavailability (cyclic guanosine monophosphate - cGMP), and thrombosis (fibrinogen, plasminogen activator inhibitor - PAI-1, e-selectin and vascular cell adhesion molecule - VCAM-1).</outcome>
      <timepoint>Measured at baseline (week 0) and at end of week 6.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All patients on haemodialysis or peritoneal dialysis for Chronic kidney disease, including patients with diabetes; Patients should be stable on dialysis for at least 6 months with adequate indices of dialysis (Fractional Reduction of Urea, FRU &gt; 0.67 or Kt/V &gt; 0.3); All patients with moderate-to-severe chronic kidney disease (GFR &lt; 40ml/min), including patients with diabetes.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Nephrotic-range proteinuria; Active upper gastro-intestinal dyspepsia; Muscular disorders; Liver and muscle enzymes &gt; 2 times upper limit of normal; Alcohol consumption &gt; 3 standard drinks/day; Use of antioxidant vitamin supplements other than multivitamin B/folic acid preparations routinely used in haemodialysis patients; Immunosuppressive therapy for renal transplantation; Cardiovascular event or unstable cardiovascular disease in preceding 6 months; Drugs known to affect lipid-metabolism (eg. fish oil supplements); Significant psychiatric disorder; Active infection.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Randomisation was performed centrally using random number tables by the Pharmacy department (distant department not involved with the trial directly) this ensuring the allocation concealment.</concealment>
    <sequence>Computer software Microsoft XP Excel to generate random number tables.  Randomisation stratified for treatment mode block 1: (predialysis, haemodialysis or peritoneal dialysis) and block 2: (diabetes mellitus or no diabetes mellitus).</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/05/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>105</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer CVL Grants</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pfizer CVL grants</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Pfizer</sponsorname>
      <sponsoraddress />
      <sponsorcountry>United States of America</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Sharan Dogra</name>
      <address>Royal Perth Hospital
Level 3 MRF Building
GPO BOX X2213
Perth WA 6847</address>
      <phone>+61 8 92240232</phone>
      <fax />
      <email>sdogra@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Sharan Dogra</name>
      <address>Royal Perth Hospital
Level 3 MRF Building
GPO BOX X2213
Perth WA 6847</address>
      <phone>+61 8 92240232</phone>
      <fax />
      <email>sdogra@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>